HMG-CoA

Abbreviation for β-hydroxy-β-methylglutaryl-CoA.

Farlex Partner Medical Dictionary © Farlex 2012

References in periodicals archive ?

3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) lyase deficiency is usually clinically evident during infancy and is characterized by vomiting, hypotonia, lethargy, metabolic acidosis, non-ketotic hypoglycemia, and Reyelike syndrome.

3-Hydroxy-3-methylglutaryl-CoA (HMG-CoA) Lyase Deficiency

Pleiotropic effects of HMG-CoA reductase inhibitors.

Inhibitory Effects of Simvastatin on Oxidized Low-Density Lipoprotein-Induced Endoplasmic Reticulum Stress and Apoptosis in Vascular Endothelial Cells

A bioactive compound known as lovastatin, found in high concentrations in the extract, successfully inhibited HMG-CoA reductase in an experiment designed to test the enzyme's activity.

Fermenting fish to reduce cholesterol

Atorvastatin is a synthetic analogue of HMG-CoA, highly effective in reducing LDL-C levels and triglycerides10.

PHARMACOKINETIC STUDY OF ATORVASTATIN AFTER SINGLE DOSE ADMINISTRATION AMONG PAKISTANI POPULATION

Inhibition of converting 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-coA) to mevalonate (initiating step in cholesterol biosynthesis pathway) accomplished by HMG-coA reductase is the target of drug development for hypercholesterolemic patients.

Modulating liver cholesterol metabolism by 3-iodothyronamine

Further, the studies conducted worldwide so far on antilipidemic activity of authenticated Ceylon cinnamon did not address its effect on HMG-CoA reductase, cholesterol esterase, and cholesterol micellization inhibitory activities and bile acid binding.

Bark Extracts of Ceylon Cinnamon Possess Antilipidemic Activities and Bind Bile Acids In Vitro

Statins are HMG-CoA inhibitors (hydroxymethylglutaryl/coenzyme A) and they lower the cholesterol levels by competitively inhibiting the HMG-CoA reductase, the final pathway in cholesterol biosynthesis [4, 8].

Severe Rhabdomyolysis as Complication of Interaction between Atorvastatin and Fusidic Acid in a Patient in Lifelong Antibiotic Prophylaxis: A Dangerous Combination

HMG-CoA reductase (HMGCR), which catalyzes the conversion of HMG-CoA to mevalonate, is the rate-limiting enzyme in cholesterol biosynthesis.

Cholesterol Synthesis Increased in the MMI-Induced Subclinical Hypothyroidism Mice Model

Statins are drugs that block a cholesterol-producing enzyme in the liver called HMG-CoA reductase.

Statins, Nonstatin therapies can help to slump the soaring cholesterol

Therapeutic approaches of dyslipidemia currently rely on the use of statins, pharmacological inhibitors of cholesterol biosynthesis that act on the key enzyme 3-hydroxy-3-methylglutaryl-Co-enzyme A (HMG-CoA) reductase (Athyros et al.

The effect of bergamot on dyslipidemia

There are four classes of lipid-lowering drugs in the market: the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (the "statins"), the fibrates (gemfibrozil, clofibrate, and fenofibrate), niacin/nicotinic acid, and the bile acid binding resins (colestipol and cholestyramine).

iHealthcareAnalyst, Inc. Announced Dyslipidemia Drugs Market to Reach USD 9.5 Billion by 2020, Decline Due to Patent Expiration and Limited Drugs Innovation

Statins might help prevent CRC through HMG-CoA reductase inhibition and other mechanisms, according to the researchers.